Apellis Pharmaceuticals shares are trading lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency has confirmed its June 2024 negative opinion on the company's intravitreal pepcetacoplan for geographic atrophy secondary to age-related macular degeneration.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals' shares are declining following the European Medicines Agency's Committee for Medicinal Products for Human Use reaffirming its negative opinion on the company's drug, intravitreal pepcetacoplan, for treating geographic atrophy secondary to age-related macular degeneration.
September 20, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock is under pressure after the European Medicines Agency's committee confirmed its negative opinion on the company's drug for geographic atrophy.
The reaffirmation of a negative opinion by a major regulatory body like the European Medicines Agency is a significant setback for Apellis Pharmaceuticals. This decision likely impacts investor sentiment negatively, leading to a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100